The Investigation on Long-term Outcomes and Prognostic Factors of Patients With Hepatitis B Related Acute-on-chronic Liver Failure
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hepatitis B
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- adverse events
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
This study is to investigate the long-term outcomes and prognostic risk factors in patients recovered from hepatitis B virus related acute on-chronic liver failure.
Detailed Description
Chronic acute liver failure (ACLF) is a systemic multi-organ failure driven by acute liver injury in the basis of chronic liver disease. The main cause of chronic acute liver failure in China is hepatitis b virus infection.Previous studies on the prognosis of acute on-chronic liver failure mainly focused on the short-term survival rate and the follow-up time was relatively short, while the study on the long-term prognosis of patients with spontaneous recovery of chronic acute liver failure was still lack-ing. Thus,this study mainly retrospectively analyzed the clinical data of patients with chronic hepatitis b related acute liver failure admitted to the department of infectious diseases, the third affiliated hospital of sun yat-sen university, and con-ducted telephone follow-up survey to analyze the long-term prognosis of patients with chronic hepatitis b related acute on-chronic liver failure.
Investigators
Liang Peng
Professer
Third Affiliated Hospital, Sun Yat-Sen University
Eligibility Criteria
Inclusion Criteria
- •Age from 18 to 65 years old;
- •The diagnosis consistent with hepatitis b associated chronic acute liver failure；
- •After hospitalization, the survival time \> 90 days；
- •The inpatient clinical data are complete.
Exclusion Criteria
- •Human immunodeficiency virus infection or congenital immune deficiency diseases;
- •Liver cancer and other tumors, autoimmune liver disease, genetic and metabolic liver disease, or other serious diseases that significantly affect patient survival;
- •Other conditions that the researchers judged not appropriate for inclusion.
Outcomes
Primary Outcomes
adverse events
Time Frame: 5 years
Adverse events included decompensated cirrhosis, hepatocellular carcinoma, liver transplantation, and death.